Eli Lilly’s One-Two Punch: Blockbuster Earnings and a Regulatory Crackdown on Copycats

Eli Lilly smashes Q1 expectations with 155% profit jump to $7.7B, as FDA moves to ban cheap compounded tirzepatide, boosting its GLP-1 dominance.

The stars are aligning for Eli Lilly. The US pharmaceutical giant has not only smashed first-quarter earnings expectations, but it is also getting a powerful tailwind from Washington. A sweeping regulatory move against cheap knockoff versions of its blockbuster weight-loss drugs is set to fortify its dominance in the GLP-1 market, just as the company reports a 56% surge in revenue to $19.8 billion.

The numbers from the first quarter of 2026 were emphatic. Adjusted net income more than doubled, jumping 155% to $7.7 billion. Investors, already buoyed by the strong performance, sent the stock up roughly 10% over the past week, with shares trading at €821.50. The company’s performance was enough to prompt management to raise its full-year revenue forecast to a range of $82 billion to $85 billion.

Volume Crushes Price Headwinds

The engine of this growth remains the company’s twin blockbusters: Mounjaro and Zepbound. Mounjaro generated global sales of $8.66 billion, while Zepbound contributed over $4 billion in the US alone. While realized selling prices dipped 13% during the quarter, a massive 65% surge in volume more than compensated for the pressure. Eli Lilly now controls roughly 60% of the US GLP-1 market and is rapidly expanding its international footprint.

CEO David Ricks sees no let-up in demand. He estimates the global number of GLP-1 users will climb from 20 million to 30 million by the end of 2026, a scenario that could quickly render the company’s upgraded annual guidance conservative.

The FDA Steps In

Adding to the bullish outlook is a decisive intervention from the US Food and Drug Administration. The agency is moving to permanently ban large-scale compounding of tirzepatide, the active ingredient in Eli Lilly’s weight-loss and diabetes drugs. For years, compounding pharmacies have been mixing cheaper versions of the drug, siphoning off patients who could not access or afford the branded product.

FDA Commissioner Marty Makary has argued that the clinical justification for compounding has evaporated, as the original medications are now widely available. The crackdown is also rooted in safety data: the agency recorded over 320 adverse events linked to compounded tirzepatide by early 2025, with incorrect dosing from multi-dose vials leading to hospitalizations.

The FDA is accepting public comments on the proposed ban until June 29, 2026. If finalized, the rule would effectively seal off a major channel for low-cost competition, further cementing Eli Lilly’s pricing power.

A Spending Spree and a New Launch

The company is not relying on regulatory goodwill alone. Armed with a massive cash flow, management has gone on an acquisition spree, spending roughly $21 billion on deals this year alone. The latest target is Centessa Pharmaceuticals, a biotech firm being acquired for nearly $8 billion. That follows the purchase of Ajax Therapeutics, a blood cancer specialist.

On the product front, Eli Lilly launched Foundayo, a new oral GLP-1 drug, in April. Access is also set to improve: starting in July, an expanded Medicare program will cap out-of-pocket costs for drugs like Zepbound at $50 per month through the end of 2026.

Analyst Optimism and a Deep Pipeline

Wall Street is taking notice. Morgan Stanley has reiterated its overweight rating on the stock, raising its price target to $1,344. Cantor Fitzgerald followed suit, lifting its target to $1,230. The bullish sentiment is underpinned by a deep development pipeline featuring 42 active Phase III programs. Clarivate analysts project that the experimental drug retatrutide alone could generate $30 billion in annual sales by 2031.

Between the earnings beat, the regulatory clampdown, and the aggressive expansion strategy, Eli Lilly is positioning itself to dominate the weight-loss drug market for years to come. For now, the only question is how much higher the bar can go.